TheraRadar
Data updated: May 26, 2026

CLOTRIMAZOLE

Infectious Disease Approved 1993-07-16

CLOTRIMAZOLE is indicated for the treatment of Candidiasis; Tinea Versicolor; Tinea Pedis; Tinea Cruris; Tinea Corporis.

Source: FDA Label • Hikma
13
Indications
--
Phase 3 Trials
32
Years on Market

Details

Status
Prescription
First Approved
1993-07-16
Routes
ORAL, TOPICAL, VAGINAL
Dosage Forms
TROCHE/LOZENGE, CREAM, SOLUTION

CLOTRIMAZOLE Approval History

1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
91 FDA actions from 1993 to 2024
Feb 2024 ORIGINAL
Update
Oct 2023 ORIGINAL
Update
Mar 2022 SUPPL
Label · Labeling

What CLOTRIMAZOLE Treats

5 indications

CLOTRIMAZOLE is approved for 5 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Candidiasis
  • Tinea Versicolor
  • Tinea Pedis
  • Tinea Cruris
  • Tinea Corporis
Source: FDA Label

CLOTRIMAZOLE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CLOTRIMAZOLE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

EXELDERM
SULCONAZOLE NITRATE
4 shared
JOURNEY
Shared indications:
OXICONAZOLE NITRATE
OXICONAZOLE NITRATE
4 shared
SUN PHARMA CANADA
Shared indications:
CLOTIC
CLOTRIMAZOLE
3 shared
CARWIN PHARM ASSOC
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT03005353 CSE Ph 2, Ph 3 completed Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Suppositories.
NCT03115073 ProF-001_Phase IIa Ph 2, Ph 3 completed ProF-001_Phase IIa
NCT02847286 IPM 036 Ph 1 completed To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)
NCT01993823 results posted G238OTIII/11IA01 Ph 3 completed Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis
NCT02713139 Frauen ACH-CLP-03(05/12) Ph 3 withdrawn Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CLOTRIMAZOLE FDA Label Details

Indications & Usage

CLOTRIMAZOLE is indicated for the treatment of Candidiasis; Tinea Versicolor; Tinea Pedis; Tinea Cruris; Tinea Corporis.

Looking for the branded version?

CLOTIC

Full clinical data, patents, trials, and competitive landscape for clotrimazole.

See CLOTIC

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.